Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MetXia gene therapy - Oxford BioMedica

Drug Profile

MetXia gene therapy - Oxford BioMedica

Alternative Names: MetXia; MetXia-MG; MetXia-P450; MetXia-VM; P450-GDEPT

Latest Information Update: 18 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Pancreatic cancer
  • Discontinued Breast cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 29 Aug 2007 MetXia gene therapy is still in phase II trials for pancreatic cancer in the UK
  • 24 Mar 2005 A clinical study has been added to the adverse events and pharmacodynamics section
  • 16 Feb 2004 Phase-II clinical trials in Pancreatic cancer in United Kingdom (intratumoural)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top